Latest Incyte News & Updates

See the latest news and media coverage for Incyte. We track all announcements, press releases, and industry mentions in real time, all in one place.

Incyte

Global biopharmaceutical company

incyte.com

Headquarters: Wilmington, United States
Company type: Public company
Number of employees: 3,500–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Incyte

In short: Incyte reported strong 2026 financial growth, raised sales guidance, and completed the $1.25 billion acquisition of Vega Therapeutics.

Company announcements

July 29 Incyte

Incyte received EU approval for Opzelura cream for atopic dermatitis

The European Commission approved it as the first steroid-free topical JAK inhibitor for adults with moderate disease, based on Phase 3b data.

July 28 Incyte

Incyte reports second quarter 2026 financial results

Total revenue of $1.67 billion with 38% growth, and updated guidance for 2026.

July 23 Incyte

Incyte publishes Phase 3 HS data

The data appeared in a Nature Medicine publication from the STOP-HS trials.

July 11 Incyte

Incyte reports 81% median bleed reduction with VGA039 in VWD

Data from Phase 1/2 multidose study showed safe and effective prophylaxis with once-monthly subcutaneous dosing.

Media coverage

July 29 Yahoo Finance

Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod

The European Commission on Wednesday approved Incyte's Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do...

July 29 Yahoo Finance

European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)

In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat...

July 29 AFP

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura ® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult...

July 29 Medical Xpress

Povorcitinib beneficial for moderate-to-severe hidradenitis suppurativa

For patients with moderate-to-severe hidradenitis suppurativa (HS), povorcitinib (an oral Janus kinase 1 inhibitor) is beneficial, according to a study published online July 23 in...

Never miss news about Incyte

Track Incyte and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Incyte competitors & trending companies

Browse news for competitors to Incyte and other trending companies.